A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib
Memorial Sloan Kettering Cancer Center
Summary
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Description
Screening portion: Patients will begin on single agent osimertinib obtained commercially at the standard dose of 80mg orally daily. Osimertinib monotherapy is currently standard of care first-line treatment for patients with metastatic EGFR-mutant lung cancers. During the screening portion of the study, patients will be treated per standard practice as decided by the treating physician using the guidance of the osimertinib product label. The patient will proceed with three cycles (21 days per cycle) of single agent osimertinib. Patients will be seen on C1D1 for osimertinib start (telemedicine…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Inital * Age ≥ 18 years * Biopsy proven metastatic non-small cell lung cancer, confirmed at enrolling institution * Somatic activating mutation in EGFR in pre-treatment tumor biopsy/ cytology from pleural fluid or cfDNA * Either have not started a prior EGFR TKI therapy or may have started osimertinib within 3 weeks of confirming eligibility and enrollment criteria of measurable disease per approval of PI, with no prior chemotherapy for treatment of metastatic disease (adjuvant therapy \> 6 months prior to study start is acceptable) * Measurable (RECIST 1.1) indicator lesi…
Interventions
- DrugOsimertinib
80mg orally daily
- DrugCarboplatin
Carboplatin (AUC 5 IV q 3 weeks)
- DrugPemetrexed
Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles
Locations (18)
- UC Davis Cancer Center (Data Collection Only)Sacramento, California
- University of California San FranciscoSan Francisco, California
- Moffitt Cancer CenterTampa, Florida
- John Hopkins Medical CenterBaltimore, Maryland
- Massachusetts General Hospital (Data Collection Only)Boston, Massachusetts
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, New Jersey